Protagenic Therapeutics, Inc. (PTIX)
0.7199
-0.02
(-2.05%)
USD |
OTCM |
Oct 23, 16:00
Protagenic Therapeutics Net Income (Quarterly) : -0.9636M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.9636M |
| March 31, 2026 | 5.084M |
| December 31, 2025 | 2.211M |
| September 30, 2025 | -0.8695M |
| June 30, 2025 | -5.058M |
| March 31, 2025 | -1.44M |
| December 31, 2024 | -1.554M |
| September 30, 2024 | -0.6408M |
| June 30, 2024 | -1.606M |
| March 31, 2024 | -1.724M |
| December 31, 2023 | -1.676M |
| September 30, 2023 | -1.397M |
| June 30, 2023 | -1.210M |
| March 31, 2023 | -0.7181M |
| December 31, 2022 | -0.6014M |
| September 30, 2022 | -0.9253M |
| June 30, 2022 | -0.6667M |
| March 31, 2022 | -1.362M |
| December 31, 2021 | -0.8904M |
| September 30, 2021 | -0.8783M |
| June 30, 2021 | -1.548M |
| March 31, 2021 | -1.206M |
| December 31, 2020 | -0.5237M |
| September 30, 2020 | -1.046M |
| June 30, 2020 | -0.5674M |
| Date | Value |
|---|---|
| March 31, 2020 | -0.4986M |
| December 31, 2019 | -0.7499M |
| September 30, 2019 | -0.1233M |
| June 30, 2019 | -0.2785M |
| March 31, 2019 | -0.5992M |
| December 31, 2018 | -0.7897M |
| September 30, 2018 | -0.4975M |
| June 30, 2018 | -0.6714M |
| March 31, 2018 | -0.5982M |
| December 31, 2017 | -0.6961M |
| September 30, 2017 | -0.4546M |
| June 30, 2017 | -0.4511M |
| March 31, 2017 | -0.6579M |
| December 31, 2016 | -0.5561M |
| September 30, 2016 | -0.4555M |
| June 30, 2016 | -0.5245M |
| March 31, 2016 | -0.7398M |
| June 30, 2015 | -0.117M |
| March 31, 2015 | -0.126M |
| December 31, 2014 | -0.139M |
| September 30, 2011 | -4.522M |
| June 30, 2011 | -6.153M |
| March 31, 2011 | -3.514M |
| December 31, 2010 | -8.164M |
| September 30, 2010 | -3.636M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | -178.92M |
| Oncolytics Biotech, Inc. | -9.442M |
| Sangamo Therapeutics, Inc. | -31.00M |
| Sarepta Therapeutics, Inc. | -4.89M |
| Anixa Biosciences, Inc. | -2.625M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 0.9636M |
| EPS Diluted (Quarterly) | -0.5323 |
| Enterprise Value | 0.7372M |
| Earnings Yield | 409.6% |
| Normalized Earnings Yield | 285.76 |